Patents by Inventor Walter Ferlin

Walter Ferlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
    Patent number: 12583922
    Abstract: This disclosure provides bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: March 24, 2026
    Assignee: Novimmune SA
    Inventors: Xavier Chauchet, Krzysztof Masternak, Limin Shang, Elise Penarrieta, Walter Ferlin
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 12297264
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: May 13, 2025
    Assignee: SWEDISH ORPHAN BIOVITRUM AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
    Patent number: 12275785
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: April 15, 2025
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 12195530
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: January 14, 2025
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
    Publication number: 20240254234
    Abstract: The present invention relates to PD-L1xCD28 bispecific antibodies which act as immune checkpoint inhibitors by binding to and blocking PD-L1 (thus preventing its engagement with PD-1 expressed on T cells) that can further deliver a costimulatory signal to T cells by clustering and agonistically engaging CD28.
    Type: Application
    Filed: October 20, 2023
    Publication date: August 1, 2024
    Inventors: Sara MAJOCCHI, Valéry MOINE, Krzysztof M. MASTERNAK, Limin SHANG, Walter FERLIN
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20240010719
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 11, 2024
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Anti-IL-6/IL-6R antibodies and methods of use thereof
    Patent number: 11613582
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: March 28, 2023
    Assignee: NovImmune S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20220389091
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: December 23, 2021
    Publication date: December 8, 2022
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF
    Publication number: 20220315654
    Abstract: This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1 (e.g. cancer).
    Type: Application
    Filed: March 22, 2022
    Publication date: October 6, 2022
    Inventors: Xavier CHAUCHET, Krzysztof MASTERNAK, Limin SHANG, Elise PENARRIETA, Walter FERLIN
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11236158
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 1, 2022
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
    Patent number: 11034760
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 15, 2021
    Assignee: Swedish Orphen Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF CXCL9 AND OTHER BIOMARKERS
    Publication number: 20210101972
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • ANTI-IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200354461
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 12, 2020
    Applicant: NovImmune, S.A.
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GUILHOT
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20200291110
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: March 26, 2020
    Publication date: September 17, 2020
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Anti-IL-6/IL-6R antibodies and methods of use thereof
    Patent number: 10759862
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 1, 2020
    Assignee: Novimmune, S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Anti—TLR4 antibodies and methods of use thereof
    Patent number: 10689441
    Abstract: This invention relates generally to anti-Toll-like Receptor 4 (TLR4 antagonists) including antibodies that specifically bind Toll-like Receptor 4 (TLR-4), to methods of using the anti-TLR4 antagonists as therapeutics and to methods of using the anti-TLR4 antagonists for inhibiting, delaying the progression of, or otherwise ameliorating a symptom of Graft-versus-Host disease (GvHD) and/or improving survival of GvHD subjects and/or transplanted biological materials in subjects.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 23, 2020
    Assignee: NovImmune SA
    Inventors: Emmanuel Monnet, Limin Shang, Susana Salgado-Pires, Walter Ferlin, Greg Elson
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20180142015
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 24, 2018
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • ANTI-IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180086839
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GULHOT
  • Anti-IL-6/IL-6R antibodies
    Patent number: 9828430
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 28, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot